{"id":24961,"date":"2025-04-13T17:43:53","date_gmt":"2025-04-13T17:43:53","guid":{"rendered":"https:\/\/purematrixchem.com\/?post_type=product&p=24961"},"modified":"2025-12-21T20:21:17","modified_gmt":"2025-12-21T19:21:17","slug":"o-dsmt-50-mg-peletler","status":"publish","type":"product","link":"https:\/\/purematrixchem.com\/tr\/magaza\/o-dsmt\/o-dsmt-50-mg-peletler\/","title":{"rendered":"O-DSMT 50mg Pelet"},"content":{"rendered":"

O-DSMT 50 mg Peletler \u2013 Sorular\u0131n\u0131z\u0131n Cevaplar\u0131<\/strong><\/p>\n

\n
\n

Ara\u015ft\u0131rma Metodolojisi K\u0131lavuzu: Pelet Halindeki O-DSMT\u2019nin Analizi ve Farmakokinetik De\u011ferlendirmesi<\/strong><\/h3>\n

1. \u00d6ns\u00f6z\u00fcn Ba\u015fl\u0131\u011f\u0131<\/strong>
\nEen specifieke titel, bijvoorbeeld:
\n\u201cYasad\u0131\u015f\u0131 O-DSMT 50 mg peletlerinin analitik ve farmakokinetik karakterizasyonu: doz do\u011frulu\u011fu \u00fczerine bir \u00e7al\u0131\u015fma ve\u00a0in vitro<\/em>\u00a0\u201ddavran\u0131\u015f.\"
\n.<\/em>
\n\u201cO-desmetiltramadol (O-DSMT) peletlerinin adli risk de\u011ferlendirmesi: safl\u0131k analizi, dozaj homojenli\u011fi ve biyolojik matrislerde saptanabilirlik.\u201d<\/p>\n

2. Inleiding en Probleemstelling<\/strong><\/p>\n

    \n
  • \n

    Achtergrond:<\/strong>\u00a0O-DSMT\u2019yi (O-Desmetiltramadol), bir opioid a\u011fr\u0131 kesici olan tramadol\u00fcn birincil aktif metaboliti olarak tan\u0131t\u0131n. O-DSMT'nin yasad\u0131\u015f\u0131 piyasada, genellikle 50 mg'l\u0131k bir etki g\u00fcc\u00fc ile pazarlanan peletler (tabletler) halinde s\u0131k\u0131\u015ft\u0131r\u0131lm\u0131\u015f bir \u2018Ara\u015ft\u0131rma Kimyasal\u0131\u2019 veya Yeni Psikoaktif Madde (NPS) olarak giderek daha fazla ortaya \u00e7\u0131kt\u0131\u011f\u0131n\u0131 a\u00e7\u0131klay\u0131n. Tramadol\u00fcn kendisinden \u00f6nemli \u00f6l\u00e7\u00fcde daha g\u00fc\u00e7l\u00fc olan \u00b5-opioid resept\u00f6r agonisti etkisini ve bununla birlikte gelen y\u00fcksek solunum depresyonu ve a\u015f\u0131r\u0131 doz riskini vurgulay\u0131n.<\/p>\n<\/li>\n

  • \n

    Probleemstelling:<\/strong>\u00a0Kritik eksiklikleri belirleyin. Bu yasad\u0131\u015f\u0131 preparatlar\u0131n ger\u00e7ek dozu ve safl\u0131\u011f\u0131 bilinmemektedir ve b\u00fcy\u00fck farkl\u0131l\u0131klar g\u00f6stermektedir. \u00d6zellikle pelet haline getirilmi\u015f form i\u00e7in farmakokinetik veriler (emilim, metabolizma) yetersizdir; bu da adli t\u0131p ve klinik konsantrasyonlar\u0131n yorumlanmas\u0131n\u0131 zorla\u015ft\u0131rmaktad\u0131r. Zararl\u0131 katk\u0131 maddelerinin (\u00f6rn. di\u011fer opioidler, kafein, sentetik kannabinoidler) varl\u0131\u011f\u0131 ek bir tehlike olu\u015fturmaktad\u0131r.<\/p>\n<\/li>\n

  • \n

    Onderzoeksvraag:<\/strong>\u00a0\u201cYasad\u0131\u015f\u0131 O-DSMT 50 mg peletlerinin farmas\u00f6tik kalitesi (doz homojenli\u011fi, safl\u0131k) nedir ve bu madde nas\u0131l bir etki g\u00f6sterir?\u201d\u00a0in vitro<\/em>\u00a0\u201dV\u00fccuda al\u0131m ve metabolizma a\u00e7\u0131s\u0131ndan?\u201d<\/p>\n<\/li>\n

  • \n

    Doelstellingen:<\/strong><\/p>\n

      \n
    • \n

      Hoofddoel:<\/strong>\u00a0Yasad\u0131\u015f\u0131 olarak ticareti yap\u0131lan O-DSMT peletlerinin farmas\u00f6tik kalitesinin de\u011ferlendirilmesi ve farmakokinetik davran\u0131\u015f\u0131n\u0131n tahmin edilmesi amac\u0131yla, analitik ve\u00a0in vitro<\/em>\u00a0yakla\u015f\u0131m.<\/p>\n<\/li>\n

    • \n

      Specifieke doelstellingen:<\/strong><\/p>\n

        \n
      1. \n

        Farmakope ilkelerine (Ph. Eur.) g\u00f6re pelet ba\u015f\u0131na doz homojenli\u011finin ve ortalama O-DSMT i\u00e7eri\u011finin belirlenmesi.<\/p>\n<\/li>\n

      2. \n

        Kimyasal safl\u0131\u011f\u0131n analiz edilmesi ve tehlikeli katk\u0131 maddeleri\/kirleticilerin taranmas\u0131.<\/p>\n<\/li>\n

      3. \n

        \u015eunun de\u011ferlendirilmesi:\u00a0in vitro<\/em>\u00a0\u00e7\u00f6z\u00fcnme h\u0131z\u0131 (dissolutie), kay\u0131t h\u0131z\u0131n\u0131 tahmin etmek i\u00e7in.<\/p>\n<\/li>\n

      4. \n

        \u015eunun ara\u015ft\u0131r\u0131lmas\u0131:\u00a0in vitro<\/em>\u00a0insan karaci\u011fer mikrozomlar\u0131 kullanarak, adli t\u0131p ama\u00e7l\u0131 tespit i\u00e7in \u00f6nemli metabolitleri tan\u0131mlamak \u00fczere metabolizma \u00e7al\u0131\u015fmas\u0131.<\/p>\n<\/li>\n<\/ol>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

        3. Edebiyat Ara\u015ft\u0131rmalar\u0131<\/strong><\/p>\n

          \n
        • \n

          Tramadol ve O-DSMT ile ilgili farmakolojik ve toksikolojik literat\u00fcr\u00fcn g\u00f6zden ge\u00e7irilmesi.<\/p>\n<\/li>\n

        • \n

          O-DSMT zehirlenmeleri ve \u00f6l\u00fcm vakalar\u0131na ili\u015fkin adli t\u0131p vaka raporlar\u0131n\u0131n analizi.<\/p>\n<\/li>\n

        • \n

          Kat\u0131 dozaj formlar\u0131ndaki opioidler ve yeni psikotrop maddeler (NPS) i\u00e7in analitik y\u00f6ntemlerin incelenmesi.<\/p>\n<\/li>\n

        • \n

          EMCDDA ve Trimbos Enstit\u00fcs\u00fc\/NDEC gibi g\u00f6zlem a\u011flar\u0131ndan elde edilen verilerin incelenmesi.<\/p>\n<\/li>\n<\/ul>\n

          4. Onderzoeksmethodologie (Materiaal en Methoden)<\/strong><\/p>\n

            \n
          • \n

            4.1 Type Onderzoek:<\/strong>\u00a0Deneysel, analitik ve\u00a0in vitro<\/em>\u00a0farmakolojik ara\u015ft\u0131rma.<\/p>\n<\/li>\n

          • \n

            4.2 \u00c7al\u0131\u015fmalar:<\/strong>\u00a0Pelet numunelerinin laboratuvar analizi ve\u00a0in vitro<\/em>\u00a0deneyler.<\/p>\n<\/li>\n

          • \n

            4.3 Malzeme:<\/strong><\/p>\n

              \n
            • \n

              Stoffen:<\/strong>\u00a0O-DSMT referans standard\u0131, izotopla i\u015faretlenmi\u015f i\u00e7 standart (\u00f6rn. O-DSMT-d6 veya tramadol-d6), insan karaci\u011fer mikrozomlar\u0131, sim\u00fcle edilmi\u015f mide ve ba\u011f\u0131rsak s\u0131v\u0131s\u0131 (\u00e7\u00f6z\u00fcnme ortam\u0131).<\/p>\n<\/li>\n

            • \n

              Apparatuur:<\/strong>\u00a0LC-MS\/MS, \u00e7\u00f6zeltileme cihaz\u0131 (kanatl\u0131 y\u00f6ntem), analitik terazi, havan, vorteks, santrif\u00fcj.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n

            • \n

              4.4 Y\u00f6ntemler:<\/strong><\/p>\n

                \n
              • \n

                Monstervoorbereiding:<\/strong>\u00a020 peleti tek tek hassas bir \u015fekilde tart\u0131n. Her birini homojen bir toz haline getirin ve analiz i\u00e7in hassas bir \u015fekilde tart\u0131lm\u0131\u015f bir k\u0131sm\u0131n\u0131 \u00e7\u00f6z\u00fcn.<\/p>\n<\/li>\n

              • \n

                Doz homojenli\u011fi ve Analiz (LC-MS\/MS):<\/strong><\/p>\n

                  \n
                • \n

                  Pellet matrisinde O-DSMT i\u00e7in hassas bir LC-MS\/MS y\u00f6ntemini do\u011frulay\u0131n. Kantifikasyon ve teyit i\u00e7in MRM ge\u00e7i\u015flerini kullan\u0131n.<\/p>\n<\/li>\n

                • \n

                  10 ayr\u0131 pelet i\u00e7indeki O-DSMT i\u00e7eri\u011fini belirleyin. Ortalamay\u0131, standart sapmay\u0131 ve RSD% de\u011ferini hesaplay\u0131n. Farmakope kriterleriyle (Ph. Eur. 2.9.40) kar\u015f\u0131la\u015ft\u0131r\u0131n.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                • \n

                  Safl\u0131k Analizi ve Tarama (LC-HRMS):<\/strong><\/p>\n

                    \n
                  • \n

                    LC-QTOF-MS ile hedef belirlemeden yap\u0131lan bir tarama y\u00f6ntemini kullanarak bilinmeyen katk\u0131 maddelerini, sentetik kirleticileri veya bozunma \u00fcr\u00fcnlerini tespit edin.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                  • \n

                    In vitro<\/em>\u00a0Dissolutietest:<\/strong><\/p>\n

                      \n
                    • \n

                      \u00d6rne\u011fin pH 1,2 (mide) ve pH 6,8 (ba\u011f\u0131rsak) ortamlar\u0131nda, k\u00fcrek y\u00f6ntemine (Ph. Eur. 2.9.3) g\u00f6re bir \u00e7\u00f6z\u00fcnme testi ger\u00e7ekle\u015ftirin. Sabit aral\u0131klarla numuneler al\u0131n ve LC-MS\/MS ile O-DSMT i\u00e7eri\u011fini analiz ederek bir \u00e7\u00f6z\u00fcnme profili olu\u015fturun.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                    • \n

                      In vitro<\/em>\u00a0Metabolizma \u00c7al\u0131\u015fmas\u0131:<\/strong><\/p>\n

                        \n
                      • \n

                        O-DSMT\u2019yi NADPH ile zenginle\u015ftirilmi\u015f insan karaci\u011fer mikrozomlar\u0131nda ink\u00fcbe edin. LC-HRMS y\u00f6ntemini kullanarak faz I metabolitlerini (\u00f6rn. N- ve O-desmetilasyonlar, hidroksilasyonlar) tan\u0131mlay\u0131n ve karakterize edin.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

                        5. Veri Analizi ve \u0130statistik<\/strong><\/p>\n

                          \n
                        • \n

                          Doz homojenli\u011fi i\u00e7in: tan\u0131mlay\u0131c\u0131 istatistikleri uygulay\u0131n ve Avrupa Farmakopesi\u2019ne g\u00f6re kabul de\u011ferini (AV) hesaplay\u0131n.<\/p>\n<\/li>\n

                        • \n

                          \u00c7\u00f6z\u00fcnme i\u00e7in: Zaman eksenine kar\u015f\u0131 serbest kalan O-DSMT\u2019nin k\u00fcm\u00fclatif y\u00fczdesini \u00e7izin.<\/p>\n<\/li>\n

                        • \n

                          Metabolizma i\u00e7in: HRMS verilerini yaz\u0131l\u0131mla analiz ederek metabolitlerin molek\u00fcl form\u00fcllerini ve par\u00e7alanma kal\u0131plar\u0131n\u0131 belirleyin.<\/p>\n<\/li>\n<\/ul>\n

                          6. Ethische, Veiligheids- en Wettelijke Overwegingen<\/strong><\/p>\n

                            \n
                          • \n

                            Veiligheid:<\/strong>\u00a0O-DSMT g\u00fc\u00e7l\u00fc bir opioiddir. Tozun solunmas\u0131ndan ve ciltle temas\u0131ndan ka\u00e7\u0131n\u0131n. Tozlar\u0131 \u00f6\u011f\u00fct\u00fcrken ve kullan\u0131rken \u00e7ekici kabin i\u00e7inde \u00e7al\u0131\u015f\u0131n. Eldiven, laboratuvar \u00f6nl\u00fc\u011f\u00fc ve g\u00f6z koruyucu giyin.<\/p>\n<\/li>\n

                          • \n

                            Wettelijk Kader:<\/strong>\u00a0O-DSMT (tramadol ile benzerlik g\u00f6steren) b\u00fcy\u00fck olas\u0131l\u0131kla \u015fu kategorinin kapsam\u0131na girer:\u00a0Afyon Kanunu (Liste II)<\/strong>. Ara\u015ft\u0131rma ama\u00e7l\u0131 sahip olma ve kullan\u0131m i\u00e7in bir\u00a0spesi\u0307fi\u0307ke vergunning<\/strong>. Numune temini i\u00e7in en uygun yol, adli t\u0131p ortakl\u0131klar\u0131 yoluyla ger\u00e7ekle\u015ftirilmesidir.<\/p>\n<\/li>\n

                          • \n

                            Ethiek:<\/strong>\u00a0\u0130\u00e7in\u00a0in vitro<\/em>\u00a0Ticari yollardan temin edilen insan karaci\u011fer mikrozomlar\u0131 ile yap\u0131lan \u00e7al\u0131\u015fmalar i\u00e7in ek METC onay\u0131 gerekmemektedir. Analitik ara\u015ft\u0131rma amac\u0131yla el konulan yasad\u0131\u015f\u0131 \u00fcr\u00fcnlerin kullan\u0131m\u0131 WMO kapsam\u0131 d\u0131\u015f\u0131ndad\u0131r, ancak bu \u00fcr\u00fcnlerin yasal olarak ge\u00e7erli bir men\u015feye sahip olmas\u0131 gerekmektedir.<\/p>\n<\/li>\n<\/ul>\n

                            7. Tijdsplanning (Gantt \u015femas\u0131)<\/strong><\/p>\n

                              \n
                            • \n

                              A\u015fama 1 (M1-2):<\/strong>\u00a0Literat\u00fcr taramas\u0131, referans standartlar\u0131n\u0131n temini ve yasal haz\u0131rl\u0131klar.<\/p>\n<\/li>\n

                            • \n

                              A\u015fama 2 (M3-4):<\/strong>\u00a0LC-MS\/MS y\u00f6ntem geli\u015ftirme ve do\u011frulama.<\/p>\n<\/li>\n

                            • \n

                              3. A\u015fama (M5-6):<\/strong>\u00a0Doz homojenli\u011fini ve safl\u0131\u011f\u0131 analiz edin (tarama).<\/p>\n<\/li>\n

                            • \n

                              4. A\u015fama (M7-8):<\/strong>\u00a0Uygulama\u00a0in vitro<\/em>\u00a0\u00e7\u00f6z\u00fcnme ve metabolizma \u00e7al\u0131\u015fmalar\u0131.<\/p>\n<\/li>\n

                            • \n

                              5. A\u015fama (M9-10):<\/strong>\u00a0Veri entegrasyonu ve risk de\u011ferlendirmesi.<\/p>\n<\/li>\n

                            • \n

                              A\u015fama 6 (M11-12):<\/strong>\u00a0Raporlama ve bilimsel yayg\u0131nla\u015ft\u0131rma.<\/p>\n<\/li>\n<\/ul>\n

                              8. Verwachte Resultaten en Discussie (Kader)<\/strong><\/p>\n

                                \n
                              • \n

                                O-DSMT i\u00e7eri\u011finde g\u00f6zle g\u00f6r\u00fcl\u00fcr bir de\u011fi\u015fkenlik (\u00f6rn. pelet ba\u015f\u0131na 30-70 mg yerine 50 mg) ve olas\u0131 bir homojenlik eksikli\u011fi.<\/p>\n<\/li>\n

                              • \n

                                Risk profilini de\u011fi\u015ftiren yayg\u0131n katk\u0131 maddelerinin belirlenmesi.<\/p>\n<\/li>\n

                              • \n

                                V\u00fccutta potansiyel emilim h\u0131z\u0131 hakk\u0131nda fikir veren bir \u00e7\u00f6z\u00fcnme profili.<\/p>\n<\/li>\n

                              • \n

                                \u0130drarda adli t\u0131p ama\u00e7l\u0131 tespit yetene\u011finin iyile\u015ftirilmesi i\u00e7in \u00f6nemli metabolitlerin (muhtemelen N-desmetil-O-DSMT) tan\u0131mlanmas\u0131.<\/p>\n<\/li>\n

                              • \n

                                Bu yasad\u0131\u015f\u0131 preparatlar\u0131n halk sa\u011fl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan genel bir risk de\u011ferlendirmesi.<\/p>\n<\/li>\n<\/ul>\n

                                9. Beperkingen van het Onderzoek<\/strong><\/p>\n

                                  \n
                                • \n

                                  In vitro<\/em>\u00a0dissolutie bir modeldir ve... olabilir\u00a0in vivo<\/em>\u00a0emilimi tam olarak tahmin edemez.<\/p>\n<\/li>\n

                                • \n

                                  Se\u00e7ilen peletler, yasad\u0131\u015f\u0131 pazar\u0131n tamam\u0131n\u0131 temsil eden bir \u00f6rneklem olmayabilir.<\/p>\n<\/li>\n

                                • \n

                                  Tan\u0131mlanan metabolitlerin biyolojik etkinli\u011fi bilinmemektedir.<\/p>\n<\/li>\n<\/ul>\n

                                  10. Referanslar<\/strong><\/p>\n

                                    \n
                                  • \n

                                    Avrupa Farmakopesi (Ph. Eur.)\u2019ndeki dozaj homojenli\u011fi ve \u00e7\u00f6z\u00fcnme ile ilgili monografiler.<\/p>\n<\/li>\n

                                  • \n

                                    SWGTOX y\u00f6ntem do\u011frulama k\u0131lavuzlar\u0131.<\/p>\n<\/li>\n

                                  • \n

                                    Tramadol ve O-DSMT\u2019nin farmakolojisiyle ilgili bilimsel yay\u0131nlar.<\/p>\n<\/li>\n

                                  • \n

                                    EMCDDA ve Trimbos Enstit\u00fcs\u00fc\u2019n\u00fcn yeni opioidler hakk\u0131ndaki raporlar\u0131.<\/p>\n<\/li>\n<\/ul>\n

                                    Essenti\u00eble Nederlandse Termen:<\/strong><\/p>\n

                                      \n
                                    • \n

                                      O-DSMT (O-Desmetiltramadol) = O-DSMT (O-Desmetiltramadol)<\/p>\n<\/li>\n

                                    • \n

                                      Peletler = Peletler (tabletler \/ taneler)<\/p>\n<\/li>\n

                                    • \n

                                      Dosisuniformiteit = Dosisuniformiteit<\/p>\n<\/li>\n

                                    • \n

                                      \u00c7\u00f6z\u00fcnme testi = \u00c7\u00f6z\u00fcnme h\u0131z\u0131 testi \/ \u00c7\u00f6z\u00fcnme incelemesi<\/p>\n<\/li>\n

                                    • \n

                                      In vitro<\/em>\u00a0metabolizma =\u00a0In vitro<\/em>\u00a0metabolizma<\/p>\n<\/li>\n

                                    • \n

                                      Safl\u0131k analizi = Safl\u0131k analizi<\/p>\n<\/li>\n

                                    • \n

                                      Katk\u0131 maddesi = Katk\u0131 maddesi \/ Sahte madde<\/p>\n<\/li>\n

                                    • \n

                                      LC-HRMS (QTOF) = LC-HRMS (QTOF)<\/p>\n<\/li>\n

                                    • \n

                                      Farmakopeye uygun = Farmakopeye uygun<\/p>\n<\/li>\n

                                    • \n

                                      Opioid resept\u00f6r agonisti = Opioid resept\u00f6r agonisti<\/p>\n<\/li>\n<\/ul>\n

                                      \u00d6nemli Uyar\u0131:<\/strong>\u00a0Bu belge\u00a0akademik \u015fablon<\/strong>. Bu denetime tabi ve potansiyel olarak hayati tehlike arz eden maddeyle yap\u0131lan ara\u015ft\u0131rmalar, t\u00fcm yasal izinlerin al\u0131nmas\u0131n\u0131 gerektirir; yetkili bir ortamda ger\u00e7ekle\u015ftirilir ve s\u0131k\u0131 g\u00fcvenlik protokollerine uyan nitelikli personel taraf\u0131ndan y\u00fcr\u00fct\u00fclmelidir. Bu t\u00fcr maddelerin yasad\u0131\u015f\u0131 ticareti ve ki\u015fisel kullan\u0131m\u0131 ciddi tehlikeler do\u011furur.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

                                      O-DSMT eigenschappen<\/h3>\n

                                      Synoniem:<\/strong> O-Desmetiltramadol, 3-(2-((dimetilamino)metil)-1-hidroksisikloheksil)fenol<\/i>
                                      \nCAS Nummer:<\/strong> 80456-81-1
                                      \nForm\u00fcl:<\/strong> C<\/span>15<\/sub>H<\/span>23<\/sub>N<\/span>O<\/span>2<\/sub>
                                      \nMolmassa:<\/strong> 249,354 g\/mol
                                      \nZuiverheid:<\/strong>\u00a0>97%<\/p>","protected":false},"featured_media":29155,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[82],"product_cat":[337,420,336,324],"product_tag":[326,727,725,728,726,729,730],"class_list":["post-24961","product","type-product","status-publish","has-post-thumbnail","product_brand-research-chemical","product_cat-o-dsmt","product_cat-o-dsmt-pellets","product_cat-overig","product_cat-pellets-for-pellet","product_tag-nl","product_tag-o-dsmt-ervaringen","product_tag-o-dsmt","product_tag-o-dsmt-bestellen","product_tag-o-dsmt-kopen","product_tag-o-dsmt-psychonaut","product_tag-what-is-o-dsmt","first","instock","taxable","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/product\/24961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/comments?post=24961"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/media\/29155"}],"wp:attachment":[{"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/media?parent=24961"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/product_brand?post=24961"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/product_cat?post=24961"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/purematrixchem.com\/tr\/wp-json\/wp\/v2\/product_tag?post=24961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}